Bain, RA back InflaRx’s $55M round after early study produces promising results
A little more than a month ago, Germany’s InflaRx rolled out some promising proof-of-concept data from a small Phase IIa study of its lead drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
